Recombinant human CD48 protein (C-6*HIS)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
C-6*HIS
Activity
EC50: 10-41 ng/mL
Cat no : Eg1005
Validation Data Gallery
Product Information
Purity | >90 %, SDS-PAGE |
Endotoxin | <0.1 EU/μg protein, LAL method |
Activity |
Immobilized Human CD48 (His tag) at 2 μg/mL (100 μL/well) can bind Human CD244 (rFc tag) with a linear range of 10-41 ng/mL. |
Expression | HEK293-derived Human CD48 protein Gln27-Ser220 (Accession# P09326) with a His tag at the C-terminus. |
GeneID | 962 |
Accession | P09326 |
PredictedSize | 21.7 kDa |
SDS-PAGE | |
Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Signaling lymphocytic activation molecule family 2 (SLAMF2, CD48) is an adhesion and costimulatory molecule expressed constitutively on most hematopoietic cells, particularly in antigen presenting cells (APC). CD48 is expressed on all the hematopoietic cells, both in human and mice, except for murine neutrophils and long term-HSC. as a number of GpI receptors do, also CD48 exists as both a membrane bound (mCD48) and a soluble (sCD48) form. CD48 can have activating roles on T cells, antigen presenting cells and granulocytes, by binding to CD2 or bacterial FimH, and through cell intrinsic effects. Interactions between CD48 and its high affinity ligand CD244 are more complex, with both stimulatory and inhibitory outcomes. CD48 expression is increased in autoimmunity and allergy diseases, and anti-CD48 monoclonal antibodies have been shown to attenuate experimental autoimmune encephalomyelitis.
References:
1.Cunyi Zou. et al. (2019). Onco Targets Ther. 12:4181-4193. 2.Shannon L McArdel. et al. (2016). Clin Immunol. 164:10-20. 3.Hadas Pahima. et al. (2019). Clin Immunol. 204:64-68. 4.Shannon L McArdel. et al. (2016). J Immunol. 197(8):3038-3048.